Abstract A055: Metabolic fitness determines T cell fate: CD39/OX40 axis controls anabolic-to-catabolic reprogramming in head and neck squamous cell carcinoma

Abstract Immunometabolic reprogramming is a key determinant of anti-tumor immunity. This study examines immunometabolic signatures in Mucosal-Associated Invariant T cells (MAIT) and conventional CD8+ tumor-infiltrating lymphocytes (TILs) from head and neck squamous cell carcinoma (HNSCC) patients treated with neoadjuvant anti-PD-1 (n=8) and anti-PD-1/IL-8 (n=7). Analyses were performed without response stratification due to the limited number of responders. Using functional-metabolic (MET) flow cytometry, we identified three CD39 expression levels (high, medium, negative) that inversely correlate with OX40 expression and define metabolic states. Strikingly, OX40, a co-stimulatory receptor linked to T-cell activation, was significantly upregulated on CD39neg MAIT cells, but not on CD39hi exhausted cells. OX40 expression was further enriched on CD39neg MAIT cells following anti-PD-1 treatment, suggesting selective activation of the non-exhausted MAIT compartment. The CD39neg/med OX40+ activated MAIT subset, compared to the OX40- subset, showed unique metabolic features, with decreased glucose-6-phosphate dehydrogenase (G6PD) and acetyl-CoA carboxylase 1 (ACC1) expression, indicating reduced pentose phosphate pathway and fatty acid synthesis capacity in both pre- and post-treatment samples. Conversely, the rate-limiting enzyme for fatty acid oxidation (FAO), CPT1A, and the electron transport chain component, Cytochrome-C, increased in the CD39neg/med OX40+ MAIT subset compared to the OX40- subset, suggesting enhanced FAO and oxidative phosphorylation. These findings indicate that the OX40+ subset transitions from biosynthetic (anabolic) to energy-generating (catabolic) metabolism. Phenograph clustering revealed similar metabolic patterns in CD39neg/med CD8+ TILs, indicating a conserved program across MAIT and CD8+ TIL subsets. Additionally, the CD39hi CD8+ TILs displayed lower OX40 expression than the CD39neg/med subsets, consistent with impaired co-stimulation and exhaustion. Furthermore, in both MAIT and CD8+ TILs, CD39neg/med OX40+ subsets display reduced H3K27Me3 expression relative to the OX40- subset, indicating that OX40+ cells may be less epigenetically restrained than OX40- cells. Therefore, this CD39neg/med OX40+ subset represents a metabolically reprogrammed subset capable of maintaining anti-tumor immunity. Functionally, CD39neg MAIT/CD8+ TILs exhibited higher Granzyme-K levels than CD39med/hi cells, with a significant increase post-treatment. In contrast, CD39hi cells showed elevated cleaved caspase-3, indicating increased apoptosis. This suggests an inverse relationship between CD39 and cytotoxic function, and a positive correlation with apoptotic susceptibility. Overall, CD39/OX40 co-expression defines metabolically fit MAIT and CD8+ T cells with enhanced anti-tumor potential. The preferential expansion of metabolically fit CD39neg/med OX40+ cells following checkpoint blockade highlights this population as critical for immunotherapy response, emphasizing CD39/OX40 immunometabolic profiling as a biomarker approach for HNSCC immunotherapy. Citation Format: Sujeetha A. Rajakumar, Namya Nanda, Chloe Kim, Dustin Dikeman, Tanguy Seiwart, Zubair Khan, Sewon Kang, Carole Fakhry, Martin P. Alphonse. Metabolic fitness determines T cell fate: CD39/OX40 axis controls anabolic-to-catabolic reprogramming in head and neck squamous cell carcinoma [abstract]. In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr A055.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Research
Published
2026-02-18
DOI
https://doi.org/10.1158/2326-6074.io2026-a055
Primary Topic
Cancer, Hypoxia, and Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract A055: Metabolic fitness determines T cell fate: CD39/OX40 axis controls anabolic-to-catabolic reprogramming in head and neck squamous cell carcinoma

Dustin A. Dikeman, Sujeetha A. Rajakumar, Chloe Kim, Namya Nanda et al.
Cancer Immunology Research
Cancer, Hypoxia, and Metabolism
article

Abstract A055: Metabolic fitness determines T cell fate: CD39/OX40 axis controls anabolic-to-catabolic reprogramming in head and neck squamous cell carcinoma

Dustin A. Dikeman, Sujeetha A. Rajakumar, Chloe Kim, Namya Nanda, Sewon Kang, Zubair Khan, Tanguy Seiwart, Martin P. Alphonse
article en

Abstract

Abstract Immunometabolic reprogramming is a key determinant of anti-tumor immunity. This study examines immunometabolic signatures in Mucosal-Associated Invariant T cells (MAIT) and conventional CD8+ tumor-infiltrating lymphocytes (TILs) from head and neck squamous cell carcinoma (HNSCC) patients treated with neoadjuvant anti-PD-1 (n=8) and anti-PD-1/IL-8 (n=7). Analyses were performed without response stratification due to the limited number of responders. Using functional-metabolic (MET) flow cytometry, we identified three CD39 expression levels (high, medium, negative) that inversely correlate with OX40 expression and define metabolic states. Strikingly, OX40, a co-stimulatory receptor linked to T-cell activation, was significantly upregulated on CD39neg MAIT cells, but not on CD39hi exhausted cells. OX40 expression was further enriched on CD39neg MAIT cells following anti-PD-1 treatment, suggesting selective activation of the non-exhausted MAIT compartment. The CD39neg/med OX40+ activated MAIT subset, compared to the OX40- subset, showed unique metabolic features, with decreased glucose-6-phosphate dehydrogenase (G6PD) and acetyl-CoA carboxylase 1 (ACC1) expression, indicating reduced pentose phosphate pathway and fatty acid synthesis capacity in both pre- and post-treatment samples. Conversely, the rate-limiting enzyme for fatty acid oxidation (FAO), CPT1A, and the electron transport chain component, Cytochrome-C, increased in the CD39neg/med OX40+ MAIT subset compared to the OX40- subset, suggesting enhanced FAO and oxidative phosphorylation. These findings indicate that the OX40+ subset transitions from biosynthetic (anabolic) to energy-generating (catabolic) metabolism. Phenograph clustering revealed similar metabolic patterns in CD39neg/med CD8+ TILs, indicating a conserved program across MAIT and CD8+ TIL subsets. Additionally, the CD39hi CD8+ TILs displayed lower OX40 expression than the CD39neg/med subsets, consistent with impaired co-stimulation and exhaustion. Furthermore, in both MAIT and CD8+ TILs, CD39neg/med OX40+ subsets display reduced H3K27Me3 expression relative to the OX40- subset, indicating that OX40+ cells may be less epigenetically restrained than OX40- cells. Therefore, this CD39neg/med OX40+ subset represents a metabolically reprogrammed subset capable of maintaining anti-tumor immunity. Functionally, CD39neg MAIT/CD8+ TILs exhibited higher Granzyme-K levels than CD39med/hi cells, with a significant increase post-treatment. In contrast, CD39hi cells showed elevated cleaved caspase-3, indicating increased apoptosis. This suggests an inverse relationship between CD39 and cytotoxic function, and a positive correlation with apoptotic susceptibility. Overall, CD39/OX40 co-expression defines metabolically fit MAIT and CD8+ T cells with enhanced anti-tumor potential. The preferential expansion of metabolically fit CD39neg/med OX40+ cells following checkpoint blockade highlights this population as critical for immunotherapy response, emphasizing CD39/OX40 immunometabolic profiling as a biomarker approach for HNSCC immunotherapy. Citation Format: Sujeetha A. Rajakumar, Namya Nanda, Chloe Kim, Dustin Dikeman, Tanguy Seiwart, Zubair Khan, Sewon Kang, Carole Fakhry, Martin P. Alphonse. Metabolic fitness determines T cell fate: CD39/OX40 axis controls anabolic-to-catabolic reprogramming in head and neck squamous cell carcinoma [abstract]. In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr A055.

Cancer Immunology ResearchVol. 14(2_Supplement)
Johns Hopkins University (US), University of Baltimore (US)
Openalex Percentile: Top 50%
Cancer, Hypoxia, and Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.